vs
EXACT SCIENCES CORP（EXAS）与美森（MATX）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是美森的1.0倍（$878.4M vs $851.9M），美森净利率更高（16.8% vs -9.8%，领先26.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs -4.3%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $42.2M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 8.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
美森公司（Matson, Inc.）是美国知名航运服务企业，总部位于夏威夷州火奴鲁鲁，成立于1882年。旗下子公司美森航运主营跨太平洋海运业务，服务覆盖夏威夷、阿拉斯加、关岛、密克罗尼西亚、太平洋诸岛、中国及日本等地区。
EXAS vs MATX — 直观对比
营收规模更大
EXAS
是对方的1.0倍
$851.9M
营收增速更快
EXAS
高出27.4%
-4.3%
净利率更高
MATX
高出26.6%
-9.8%
自由现金流更多
EXAS
多$78.2M
$42.2M
两年增速更快
EXAS
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $851.9M |
| 净利润 | $-86.0M | $143.1M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 16.9% |
| 净利率 | -9.8% | 16.8% |
| 营收同比 | 23.1% | -4.3% |
| 净利润同比 | 90.1% | 11.8% |
| 每股收益（稀释后） | $-0.45 | $4.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMATX
| Q4 25 | $878.4M | $851.9M | ||
| Q3 25 | $850.7M | $880.1M | ||
| Q2 25 | $811.1M | $830.5M | ||
| Q1 25 | $706.8M | $782.0M | ||
| Q4 24 | $713.4M | $890.3M | ||
| Q3 24 | $708.7M | $962.0M | ||
| Q2 24 | $699.3M | $847.4M | ||
| Q1 24 | $637.5M | $722.1M |
净利润EXASMATX
| Q4 25 | $-86.0M | $143.1M | ||
| Q3 25 | $-19.6M | $134.7M | ||
| Q2 25 | $-1.2M | $94.7M | ||
| Q1 25 | $-101.2M | $72.3M | ||
| Q4 24 | $-864.6M | $128.0M | ||
| Q3 24 | $-38.2M | $199.1M | ||
| Q2 24 | $-15.8M | $113.2M | ||
| Q1 24 | $-110.2M | $36.1M |
毛利率EXASMATX
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASMATX
| Q4 25 | -9.4% | 16.9% | ||
| Q3 25 | -3.0% | 18.3% | ||
| Q2 25 | -0.3% | 13.6% | ||
| Q1 25 | -13.6% | 10.5% | ||
| Q4 24 | -122.8% | 16.6% | ||
| Q3 24 | -5.6% | 25.2% | ||
| Q2 24 | -3.8% | 14.7% | ||
| Q1 24 | -16.7% | 5.1% |
净利率EXASMATX
| Q4 25 | -9.8% | 16.8% | ||
| Q3 25 | -2.3% | 15.3% | ||
| Q2 25 | -0.1% | 11.4% | ||
| Q1 25 | -14.3% | 9.2% | ||
| Q4 24 | -121.2% | 14.4% | ||
| Q3 24 | -5.4% | 20.7% | ||
| Q2 24 | -2.3% | 13.4% | ||
| Q1 24 | -17.3% | 5.0% |
每股收益（稀释后）EXASMATX
| Q4 25 | $-0.45 | $4.47 | ||
| Q3 25 | $-0.10 | $4.24 | ||
| Q2 25 | $-0.01 | $2.92 | ||
| Q1 25 | $-0.54 | $2.18 | ||
| Q4 24 | $-4.69 | $3.69 | ||
| Q3 24 | $-0.21 | $5.89 | ||
| Q2 24 | $-0.09 | $3.31 | ||
| Q1 24 | $-0.60 | $1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $141.9M |
| 总债务越低越好 | — | $361.2M |
| 股东权益账面价值 | $2.4B | $2.8B |
| 总资产 | $5.9B | $4.6B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EXASMATX
| Q4 25 | $964.7M | $141.9M | ||
| Q3 25 | $1.0B | $92.7M | ||
| Q2 25 | $858.4M | $59.1M | ||
| Q1 25 | $786.2M | $122.0M | ||
| Q4 24 | $1.0B | $266.8M | ||
| Q3 24 | $1.0B | $270.3M | ||
| Q2 24 | $946.8M | $168.2M | ||
| Q1 24 | $652.1M | $25.9M |
总债务EXASMATX
| Q4 25 | — | $361.2M | ||
| Q3 25 | — | $370.9M | ||
| Q2 25 | — | $341.3M | ||
| Q1 25 | — | $351.1M | ||
| Q4 24 | — | $361.2M | ||
| Q3 24 | — | $370.9M | ||
| Q2 24 | — | $381.0M | ||
| Q1 24 | — | $390.8M |
股东权益EXASMATX
| Q4 25 | $2.4B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.4B | $2.6B | ||
| Q4 24 | $2.4B | $2.7B | ||
| Q3 24 | $3.2B | $2.6B | ||
| Q2 24 | $3.2B | $2.4B | ||
| Q1 24 | $3.1B | $2.4B |
总资产EXASMATX
| Q4 25 | $5.9B | $4.6B | ||
| Q3 25 | $5.9B | $4.6B | ||
| Q2 25 | $5.8B | $4.5B | ||
| Q1 25 | $5.7B | $4.5B | ||
| Q4 24 | $5.9B | $4.6B | ||
| Q3 24 | $6.7B | $4.4B | ||
| Q2 24 | $6.7B | $4.3B | ||
| Q1 24 | $6.4B | $4.2B |
负债/权益比EXASMATX
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $176.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $42.2M |
| 自由现金流率自由现金流/营收 | 13.7% | 5.0% |
| 资本支出强度资本支出/营收 | 3.6% | 15.8% |
| 现金转化率经营现金流/净利润 | — | 1.24× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $153.7M |
8季度趋势，按日历期对齐
经营现金流EXASMATX
| Q4 25 | $151.7M | $176.9M | ||
| Q3 25 | $219.9M | $175.6M | ||
| Q2 25 | $89.0M | $105.6M | ||
| Q1 25 | $30.8M | $89.0M | ||
| Q4 24 | $47.1M | $174.7M | ||
| Q3 24 | $138.7M | $248.6M | ||
| Q2 24 | $107.1M | $307.9M | ||
| Q1 24 | $-82.3M | $36.6M |
自由现金流EXASMATX
| Q4 25 | $120.4M | $42.2M | ||
| Q3 25 | $190.0M | $92.4M | ||
| Q2 25 | $46.7M | $19.3M | ||
| Q1 25 | $-365.0K | $-200.0K | ||
| Q4 24 | $10.7M | $49.3M | ||
| Q3 24 | $112.6M | $189.0M | ||
| Q2 24 | $71.2M | $238.1M | ||
| Q1 24 | $-120.0M | $-18.7M |
自由现金流率EXASMATX
| Q4 25 | 13.7% | 5.0% | ||
| Q3 25 | 22.3% | 10.5% | ||
| Q2 25 | 5.8% | 2.3% | ||
| Q1 25 | -0.1% | -0.0% | ||
| Q4 24 | 1.5% | 5.5% | ||
| Q3 24 | 15.9% | 19.6% | ||
| Q2 24 | 10.2% | 28.1% | ||
| Q1 24 | -18.8% | -2.6% |
资本支出强度EXASMATX
| Q4 25 | 3.6% | 15.8% | ||
| Q3 25 | 3.5% | 9.5% | ||
| Q2 25 | 5.2% | 10.4% | ||
| Q1 25 | 4.4% | 11.4% | ||
| Q4 24 | 5.1% | 14.1% | ||
| Q3 24 | 3.7% | 6.2% | ||
| Q2 24 | 5.1% | 8.2% | ||
| Q1 24 | 5.9% | 7.7% |
现金转化率EXASMATX
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 1.12× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.36× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | 2.72× | ||
| Q1 24 | — | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MATX
| Ocean Transportation Segment | $704.2M | 83% |
| Logistics Services Segment | $147.7M | 17% |
